1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Post-Operative Pain - Pipeline Review, H1 2016

Post-Operative Pain - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 200 pages

Post-Operative Pain - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Post-Operative Pain - Pipeline Review, H1 2016’, provides an overview of the Post-Operative Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
- The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
- The report assesses Post-Operative Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post-Operative Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Post-Operative Pain - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Post-Operative Pain Overview 9
Therapeutics Development 10
Pipeline Products for Post-Operative Pain - Overview 10
Pipeline Products for Post-Operative Pain - Comparative Analysis 11
Post-Operative Pain - Therapeutics under Development by Companies 12
Post-Operative Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Post-Operative Pain - Products under Development by Companies 20
Post-Operative Pain - Companies Involved in Therapeutics Development 24
A. Menarini Industrie Farmaceutiche Riunite Srl 24
AcelRx Pharmaceuticals, Inc. 25
Adynxx, Inc. 26
Amorsa Therapeutics Inc. 27
AngioChem Inc. 28
AskAt Inc. 29
Boehringer Ingelheim GmbH 30
Cara Therapeutics, Inc. 31
Chong Kun Dang Pharmaceutical Corp. 32
Colby Pharmaceutical Company 33
Cytogel Pharma, LLC 34
DURECT Corporation 35
Echo Pharmaceuticals B.V. 36
Envisia Therapeutics Inc. 37
Flexion Therapeutics, Inc. 38
Fujimoto Pharmaceutical Corporation 39
Galleon Pharmaceuticals 40
Grunenthal GmbH 41
GW Pharmaceuticals Plc 42
Heron Therapeutics, Inc. 43
Immupharma Plc 44
INSYS Therapeutics, Inc. 45
Laboratorios Del Dr. Esteve S.A. 46
Lipocure Ltd. 47
Liquidia Technologies, Inc. 48
Medtronic plc 49
Navigen Pharmaceuticals, Inc. 50
Orbis Biosciences, Inc. 51
Orion Oyj 52
PainReform Ltd. 53
Pharmazz, Inc. 54
PhytoHealth Corporation 55
Proteus SA 56
Recro Pharma, Inc. 57
Relmada Therapeutics, Inc. 58
Serina Therapeutics, Inc. 59
SteadyMed Therapeutics, Inc. 60
Takeda Pharmaceutical Company Limited 61
The Medicines Company 62
Trevena, Inc. 63
Post-Operative Pain - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 69
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
(bupivacaine hydrochloride + meloxicam) - Drug Profile 76
(dexketoprofen + tramadol hydrochloride) - Drug Profile 77
AM-4 - Drug Profile 78
AMS-410 ER12 - Drug Profile 79
ANG-2002 - Drug Profile 80
ARX-04 - Drug Profile 81
AYX-1 - Drug Profile 83
BI-1026706 - Drug Profile 84
bupivacaine ER - Drug Profile 85
bupivacaine hydrochloride - Drug Profile 86
bupivacaine hydrochloride - Drug Profile 87
bupivacaine hydrochloride SR - Drug Profile 89
buprenorphine hydrochloride - Drug Profile 92
CKD-943 - Drug Profile 93
CPC-123 - Drug Profile 94
CR-845 - Drug Profile 95
Cyt-1010 - Drug Profile 98
dexmedetomidine hydrochloride - Drug Profile 100
difluprednate XR - Drug Profile 102
dronabinol - Drug Profile 103
Drug for Post Operative Pain - Drug Profile 105
E-52862 - Drug Profile 106
ECP-1014 - Drug Profile 108
fadolmidine hydrochloride - Drug Profile 109
fentanyl - Drug Profile 111
FX-007 - Drug Profile 112
GAL-044 - Drug Profile 113
grapiprant - Drug Profile 114
IPP-102199 - Drug Profile 116
ketamine hydrochloride - Drug Profile 117
ketamine hydrochloride ER - Drug Profile 119
ketorolac tromethamine - Drug Profile 120
levorphanol tartrate ER - Drug Profile 121
MDT-10013 - Drug Profile 123
meloxicam - Drug Profile 124
meloxicam ER - Drug Profile 125
nabiximols - Drug Profile 126
nalbuphine hydrochloride - Drug Profile 129
neosaxitoxin - Drug Profile 130
oliceridine - Drug Profile 132
PMZ-2010 - Drug Profile 134
RBM-004 - Drug Profile 136
ropivacaine - Drug Profile 137
ropivacaine ER - Drug Profile 138
SER-226 - Drug Profile 139
sufentanil citrate - Drug Profile 140
Synthetic Peptides for Pain - Drug Profile 143
tapentadol hydrochloride IR - Drug Profile 144
tramadol hydrochloride - Drug Profile 146
tramadol hydrochloride ER - Drug Profile 147
URB-937 - Drug Profile 148
VVZ-149 - Drug Profile 149
Post-Operative Pain - Recent Pipeline Updates 150
Post-Operative Pain - Dormant Projects 182
Post-Operative Pain - Discontinued Products 187
Post-Operative Pain - Product Development Milestones 188
Featured News and Press Releases 188
Appendix 196
Methodology 196
Coverage 196
Secondary Research 196
Primary Research 196
Expert Panel Validation 196
Contact Us 196
Disclaimer 197

List of Tables
Number of Products under Development for Post-Operative Pain, H1 2016 13
Number of Products under Development for Post-Operative Pain - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Development by Companies, H1 2016 (Contd..2) 18
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Development, H1 2016 21
Comparative Analysis by Unknown Stage Development, H1 2016 22
Products under Development by Companies, H1 2016 23
Products under Development by Companies, H1 2016 (Contd..1) 24
Products under Development by Companies, H1 2016 (Contd..2) 25
Products under Development by Companies, H1 2016 (Contd..3) 26
Post-Operative Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 27
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2016 28
Post-Operative Pain - Pipeline by Adynxx, Inc., H1 2016 29
Post-Operative Pain - Pipeline by Amorsa Therapeutics Inc., H1 2016 30
Post-Operative Pain - Pipeline by AngioChem Inc., H1 2016 31
Post-Operative Pain - Pipeline by AskAt Inc., H1 2016 32
Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2016 33
Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H1 2016 34
Post-Operative Pain - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 35
Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H1 2016 36
Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H1 2016 37
Post-Operative Pain - Pipeline by DURECT Corporation, H1 2016 38
Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2016 39
Post-Operative Pain - Pipeline by Envisia Therapeutics Inc., H1 2016 40
Post-Operative Pain - Pipeline by Flexion Therapeutics, Inc., H1 2016 41
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H1 2016 42
Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H1 2016 43
Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2016 44
Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H1 2016 45
Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H1 2016 46
Post-Operative Pain - Pipeline by Immupharma Plc, H1 2016 47
Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H1 2016 48
Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 49
Post-Operative Pain - Pipeline by Lipocure Ltd., H1 2016 50
Post-Operative Pain - Pipeline by Liquidia Technologies, Inc., H1 2016 51
Post-Operative Pain - Pipeline by Medtronic plc, H1 2016 52
Post-Operative Pain - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 53
Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H1 2016 54
Post-Operative Pain - Pipeline by Orion Oyj, H1 2016 55
Post-Operative Pain - Pipeline by PainReform Ltd., H1 2016 56
Post-Operative Pain - Pipeline by Pharmazz, Inc., H1 2016 57
Post-Operative Pain - Pipeline by PhytoHealth Corporation, H1 2016 58
Post-Operative Pain - Pipeline by Proteus SA, H1 2016 59
Post-Operative Pain - Pipeline by Recro Pharma, Inc., H1 2016 60
Post-Operative Pain - Pipeline by Relmada Therapeutics, Inc., H1 2016 61
Post-Operative Pain - Pipeline by Serina Therapeutics, Inc., H1 2016 62
Post-Operative Pain - Pipeline by SteadyMed Therapeutics, Inc., H1 2016 63
Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 64
Post-Operative Pain - Pipeline by The Medicines Company, H1 2016 65
Post-Operative Pain - Pipeline by Trevena, Inc., H1 2016 66
Assessment by Monotherapy Products, H1 2016 67
Assessment by Combination Products, H1 2016 68
Number of Products by Stage and Target, H1 2016 70
Number of Products by Stage and Mechanism of Action, H1 2016 73
Number of Products by Stage and Route of Administration, H1 2016 76
Number of Products by Stage and Molecule Type, H1 2016 78
Post-Operative Pain Therapeutics - Recent Pipeline Updates, H1 2016 153
Post-Operative Pain - Dormant Projects, H1 2016 185
Post-Operative Pain - Dormant Projects (Contd..1), H1 2016 186
Post-Operative Pain - Dormant Projects (Contd..2), H1 2016 187
Post-Operative Pain - Dormant Projects (Contd..3), H1 2016 188
Post-Operative Pain - Dormant Projects (Contd..4), H1 2016 189
Post-Operative Pain - Discontinued Products, H1 2016 190

List of Figures
Number of Products under Development for Post-Operative Pain, H1 2016 13
Number of Products under Development for Post-Operative Pain - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Products, H1 2016 21
Assessment by Monotherapy Products, H1 2016 67
Assessment by Combination Products, H1 2016 68
Number of Products by Top 10 Targets, H1 2016 69
Number of Products by Stage and Top 10 Targets, H1 2016 69
Number of Products by Top 10 Mechanism of Actions, H1 2016 72
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 72
Number of Products by Top 10 Routes of Administration, H1 2016 75
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 75
Number of Products by Molecule Types, H1 2016 77
Number of Products by Stage and Molecule Types, H1 2016 77

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.